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Abstract
Human cytomegalovirus (HCMV) is the most common cause of severe morbidity and mortality in immune-
compromised individuals. This study was conducted to determine the incidence of HCMV infection in HCV patients
who either spontaneously cleared the virus or progressed to chronic HCV infection. The study included a total of
eighty four cases (48 females and 36 males) that were referred to blood banks for blood donation with an age
range of 18-64 years (mean age 37.62 ± 10.03 years). Hepatitis C virus RNA and HCMV DNA were detected in sera
by RT-nested PCR and nested PCR respectively in all subjects. Immunoglobulin G levels for HCV and HCMV were
determined. Besides, IgM antibodies for HCMV infection were also determined in subjects’ sera. Fifty three out of
84 cases (63%) were positive for HCV-RNA while 31 (37%) cases had negative HCV RNA. Forty six (87%) and 13
(25%) cases out of 53 HCV RNA positive patients were positive for HCMV IgG and IgM antibodies respectively.
While 20 of 53 cases (38%) had detectable HCMV DNA. To examine the role of HCMV infection in HCV
spontaneous resolution, two groups of HCV patients, group 1) chronic HCV infection (positive HCV RNA and
positive IgG antibodies) vs group 2) spontaneous resolution (negative HCV RNA and positive IgG antibodies) were
compared. The percentages of positive CMV IgG and IgM results is higher in chronic HCV patient than those in
spontaneously cleared HCV patients and the difference is highly statistically significant (P value < 0.001). Also, there
is a general trend towards elevated levels of CMV IgG antibodies in HCV chronic patients than those in
spontaneously cleared HCV patients (P value < 0.02). HCMV DNA detection in group 1 was more than twice the
value observed in group 2 (38% vs 14.3%, P value < 0.001). Moreover, levels of liver enzymes were significantly
higher in HCV RNA positive cases co-infected with HCMV DNA than HCMV negative cases (P value < 0.001). The
results indicate the role of HCMV in the liver pathogenesis. We conclude that chronic HCV patients co-infected
with HCMV infection can be regarded as high risk groups for liver disease progression where they should be
monitored for the long term outcome of the disease.
Keywords: Hepatitis C virus, Human Cytomegalovirus DNA, Co-infection
Introduction
The importance and the interest of HCMV as a pathogen
have increased over the past two decades. Approximately
70-100% of the world’s populations are carriers of the
virus [1] and it has become the most common cause of
severe morbidity and mortality in immune compromised
individuals [2]. A primary HCMV infection is followed by
a life-long persistence of the virus in a latent state, and
reactivation may occur later in life [3]. Therefore, reacti-
vation of the virus is seen during periods of down-regula-
tion of the immune system, such as drug treatment and
illness-related stress, or during on-going activation of
the immune system such as inflammatory diseases, or
co-infection with other pathogens [4]. HCMV can infect
virtually all organ tissues, but manifestations of organ
involvement generally include symptoms from the liver,
the lungs, the intestine and the CNS [5]. Cytomegalovirus
is passed from person to person through close contact
with body fluids, such as saliva, semen, vaginal fluids,
blood, urine, tears and breast milk. Therefore, people can
get CMV through sex, breastfeeding, blood transfusions
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HCMV in human liver cells was analyzed in cell culture
and in tissue sections from patients with HCMV hepati-
t i s ,a n di tw a sc o n c l u d e dt h a tH C M Vc a nc a u s ed i r e c t
liver paranchymal damage by efficient cytolytic infection
of hepatocytes [6,7]. Human CMV hepatitis occurs as
part of disseminated CMV infection. It occurs mainly
among liver or kidney transplant recipients or immuno-
suppressed persons [8,9], however many cases of CMV
hepatitis in immunocompetent hosts have also been
reported [10,11] so that mild-moderately elevated levels
of transaminases and various histopathological changes
of the liver were encountered in these patients. On the
other hand, HCV is a major health problem in Egypt
[12,13]. We have recently shown that co-infection with
HCMV could dramatically diminish the possibility of
achieving SVR to peg IFN + RBV treatment in chronic
HCV patients [14]. This study aims to investigate the
incidence of co-infection of HCMV with HCV (either
persistent or spontaneously cleared) in samples referred
to several blood banks in Egypt.
Material and methods
Approval ethics
This research was approved by the Review Board of
National Liver Institute, Menoufia University with refer-
ence number NLI 0003413 FW0000227
Study population
Eighty- four subjects who were referred to blood banks in
Mansoura city (North Delta of Egypt) for blood donation
during the period between February and May 2010 were
enrolled in this study. The 84 cases included 48 females
and 36 males, with age range 18-54 ± mean of (37.62 ±
10.03) years. Subjects were divided into two groups;
patients who were positive for HCV IgG antibodies (n =
67) and negative control group (n = 17) who were negative
for HCV, HIV and HBV antibodies. Informed consents
were obtained from each subject before collecting serum
and whole blood samples. The age, sex, antibodies against
HCV (anti-HCV IgG), antibodies against HCMV (anti-
HCMV IgM, anti-HCMV IgG), HCV RNA, HCMV DNA
levels, and liver enzyme levels (ALT and AST) were
assessed and recorded for both patients and controls.
Detection of HCV IgG antibodies
Serum samples were collected from all studied subjects to
confirm the presence of HCV IgG Abs. HCV IgG Abs
were detected using (Diagnostic Automation, INC 23961
Craftsman Road, Suite D/E/F, Calabasas, CA 91302, USA).
Detection of HCV RNA in all samples
Presence of HCV viremia was confirmed by reverse tran-
scription-PCR using nested primers derived from the
highly conserved 5’ un-translated region. Serum samples
were collected from all cases. Then RNA was extracted
from 200 μl of all serum samples using the acid guani-
dium thiocyanate-phenol-chloroform method [15]. Pri-
mer sets used in the detection of HCV RNA were as
follow: P1: 5’ GGTGCACGGTCTACGAGACCTC 3’ -
P2 forward primer: 5’ AACTACTGTCTTCACGCAGAA
3’ - P3 reverse primer: 5’ TGCTCATGGTGCACGG
TCTA 3’- nested reverse primer P4: 5’ ACTCGGCTAG-
CAGTCTCGCG 3’ and nested forward primer P5: 5’
GTGCAGCCTCCAGGACCC 3’. All primers were pur-
chased from (Promega, Madison WI, USA). The nested
PCR amplification was done in a volume of 50 μl; and the
PCR protocol consisted of a reverse transcription step at
37°C for 60 min by using 20 U of cloned Avian Myloblas-
tosis Virus (AMV) reverse transcriptase, 1 × buffer (sup-
plied with the enzyme), (QBIOGENE, USA), 200-400 ng
of total cellular RNA as template, 40 units of RNAsin
(Clonetech, USA), 0.2 mmol / lf r o me a c hd N T P( P r o -
mega, Madison, Wisconsin,U S A )a n d1 0p m o l ef r o m
primer (P1). First round amplification was done on 10 ul
from the first cDNA strand synthesis reaction using 10
pmole from each of (P2) forward primer and (P3) reverse
primer, 0.2 mmol/l from each dNTP (Promega, Madison,
Wisconsin, USA), 2 units of Taq DNA polymerase (Pro-
mega, Madison, Wisconsin, USA) and 1 × buffer supplied
with the enzyme. The second round amplification was
done similar to the first round, except for using the
nested primers (P4) and (P5) as well as 10 ul from the
first round PCR product. Thermal protocols for both
rounds were 1 min. at 94°C, 1 min at 55°C and 1 min at
72°C for 30 cycles. The products of nested RT-PCR were
analyzed on 2% agarose gel electrophoresis.
Serological analysis of HCMV infection
Human CMV IgM and IgG antibodies were detected in all
samples by the qualitative ELISA test using commercially
available CMV kits (BioCheck, Foster City, CA, USA).
Tests were done according to the manufacturer instruc-
tions and results of HCMV IgM and IgG were expressed
as O.D. units.
Detection of HCMV DNA
Total DNA was extracted from 300 μl serum sample using
Wizard
® DNA purification mini kit, (Promega, Madison,
Wisconsin, USA), following the instructions of the manu-
facturer. Human CMV DNA was amplified using primers
derived from the gB region of CMV genome and PCR pro-
tocols were followed as described previously [16,17]. The
amplification mixture contained 3 μl of DNA extract, 10
pmole of each primer gB1: 5’ GAGGACAACGAAATCC
TGTTGGGCA 3’ and gB2: 5’ GTCGACGGTGGAGA-
TACTGCTGAGG 3’, 0.2 mmol/l from each dNTP (Pro-
mega, Madison, Wisconsin, USA), 2 units of Taq DNA
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buffer supplied with the enzyme. Two ul from the 1
st PCR
product were used in a nested-PCR containing the same
conditions as mentioned above except for using nested
primers gBn1: 5’ ACCACCGCACTGAGGAATGTCAG 3’
and gBn2: 5’ TCAATCATGCGTTTGAAGAGGTA 3’.
The thermal cycling protocol was as follows: 1 min. at
94°C, 1 min at 55°C and 1 min at 72°C for 30 cycles.
Nested amplification products were visualized on 2% agar-
ose gel electrophoresis and stained with ethidium bromide.
Liver Enzyme levels
Alanine Amino Transferase (ALT) (normal range, 40 U/L)
and Aspartate Amino Transferase (AST) (normal range,
38 U/L) levels were measured in all samples with commer-
cial Kits (Siemens Healthcare Diagnostic Inc., USA)
according to the manufacturer instructions.
Statistical analysis
All statistical analyses were performed using the SPSS
9.0 statistical software program. The statistical signifi-
cance of difference was considered when p ≤ 0.05.
Results
Prevalence of HCV IgG Abs and HCV RNA in studied
subjects
The results of HCV IgG Abs showed that 67 patients were
positive for HCV IgG Abs while 17 were negative for HCV
IgG Abs. The presence of HCV viremia was confirmed by
RT-nested PCR. The RT-PCR products of HCV RNA in
some subjects are shown in Figure 1. A result was consid-
ered positive when a clear 174-bp product was visible on
agarose gel stained with ethidium bromide. In the sixty-
seven patients who were positive for HCV IgG Abs, HCV
RNA was detected only in fifty three subjects.
Patients were classified according to the results of HCV
IgG Abs and HCV RNA as follows: fifty three patients (31
females and 22 males) were positive for (both HCV RNA
and HCV Abs) and they are described as group (1), while
31 cases (17 females and 14 males) were negative for HCV
RNA. Among the later category (negative HCV RNA) 14
cases had detectable HCV IgG Abs (negative HCV RNA,
positive HCV Abs) and were referred to as group (2) while
17 cases were negative for both HCV RNA and IgG Abs),
and they are described as group (3).
Prevalence of HCMV Abs in chronic HCV patients versus
controls
To investigate whether the prevalence of HCMV Abs
(IgG and IgM) is higher in chronic HCV patients (group
1) than in comparable control subjects (groups 2 and 3),
titers of both classes of immunoglobulins were measured
in all subjects groups. Thirteen (25%) and 46 (87%) out
of 53 chronic HCV patients (group 1) had detectable IgM
and IgG HCMV Abs respectively. No gender preference
was noted (6/13 males, 7/13 females were positive for
HCMV IgM and 21/46 males, 25/46 females were posi-
tive for HCMV IgG). In group 2 (negative HCV RNA
positive Abs) 2/14 (14.3%) and 11/14 (78.6%) were posi-
tive for HCMV IgM and IgG respectively. While in group
3 (negative for both HCV RNA and Abs), 3/17 (17.6%)
and 9/17 (53%) were positive for IgM and IgG HCMV
Abs respectively. The results depicted in Figure 2 showed
that percentage of positive CMV IgG and IgM is higher
in chronic HCV patients than those in spontaneously
cleared HCV patients and the difference is highly statisti-
cally significant (P value < 0.001). Results showed that
Figure 1 RT nested PCR results of serum samples lane 1, 2, 3
and 6 were positive for HCV RNA while lanes 5, 7, 8 and 9
were negative for HCV.
Figure 2 Measurement of liver function tests (ALT and AST) in
different studies groups. ALT: Alanine Amino Transferase. AST:
Aspartate Amino Transferase. NS: Non Significance
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(group 3) while 87% in chronic HCV patients had IgG
HCMV Abs vs 78.6% in spontaneously cleared HCV
patients (group 2). Also, there is a general trend towards
elevated levels of CMV IgG antibodies in chronic HCV
patients (0.973 ± 0.61) than those in spontaneously
cleared HCV patients (0.625 ± 0.42), P value < 0.02.
Prevalence of HCMV DNA in chronic HCV patients versus
controls
The nested PCR product of CMV gB gene in some sub-
jects is shown in Figure 3. A result was considered positive
when a clear 100-bp product was visible on agarose gel
stained with ethidium bromide. The results displayed in
Figure 4 demonstrated that 20/53 (38%) chronic HCV
patients had detectable HCMV DNA in their sera, com-
pared with 2/14 (14.3%) of HCMV DNA positivity in
group 2 (spontaneously cleared HCV infection group,
negative RNA, positive Ab) and 5/17 (29.4%) in group 3
(control subjects, negative for both HCV RNA and Abs).
Of the twenty positive HCMV DNA in chronic HCV cases
17 (85%) had detectable HCMV IgG while 13 (65%) only
had detectable IgM with no gender preference. The
observed difference between HCMV DNA prevalence in
chronic HCV patients (38%) and spontaneously cleared
HCV patients (14.3%) was highly statistically significant
(P < 0.001).
Levels of ALT & AST among study groups
The results presented in Figure 2 clearly demonstrated a
gradual decline in both ALT and AST levels from group 1
to group 2 and group 3. In HCV persistent group, serum
ALT levels (mean: 82.7 ± 20.6 IU/L) and AST (mean: 79.2
± 21.7 IU/L). In spontaneously cleared group serum ALT
mean levels were 42.9 ± 9.8 IU/L) and AST were 39.4 ±
10.75 IU/L) while in negative control group 3 where
serum ALT mean levels were 33.6 ± 10.7 IU/L and AST
mean levels were 32.6 ± 11.4 IU/L). Serum ALT and AST
levels were significantly higher in group 1 than in group 2
and group 3 (P value < 0.001) with no significant
difference between groups 2 and 3. Interestingly, in
HCMV-positive chronic HCV patients, both ALT (mean:
93.2 ± 24.9 IU/L) and AST levels (mean: 90.2 ± 24.6 IU/L)
were higher than that of HCMV-negative chronic HCV
patients where mean ALT values were 71.85 ± 15.1 IU/L)
and AST were 70.5 ± 16.9 IU/L). The difference was
highly statistically significant (P value < 0.001) as shown in
Figure 5.
Discussion
Cytomegalovirus is a ubiquitous b-herpes virus that affects
60-80% of the human population. Infection with CMV is
more widespread in developing countries. In general,
HCMV infections are effectively controlled by the immune
system, but without the ultimate clearance of the virus.
Instead, the viral genome is retained at specific sites in a
Figure 3 Nested PCR results of HCMV DNA in serum samples.
Figure 4 D e t e c t i o no fH C M VD N A ,H C M VI g Ga n dH C M VI g M
antibodies the studied groups.
Figure 5 Measurement of ALT in patients positive and
negative for HCMV DNA in the different studied groups. ALT:
Alanine Amino Transferase. + Ve: Positive. -Ve: Negative. NS: Non
Significance
Tabll et al. Virology Journal 2011, 8:343
http://www.virologyj.com/content/8/1/343
Page 4 of 6latent state out of which reactivation to recurrent infection
can occur [18]. The diagnosis of active CMV infection was
b a s e do nt h ed e t e c t i o no fC M Vr e p l i c a t i o ni nt h eb l o o d .
Therefore reactivation of CMV in the absence of an effec-
tive immune response is central to the pathogenesis of the
disease [2]. In this study, we investigated the incidence of
HCMV infection in Egyptian HCV patients who either
spontaneously cleared the virus or progressed to chronic
HCV infection and we examined the potential role that
CMV plays in HCV progression. The present data showed
that the percent of positive HCMV Abs were significantly
higher (P < 0.001) in chronic HCV patient than those in
spontaneously cleared HCV patients. Also, the CMV DNA
was detected in 38% of chronic HCV infected patients
(65% of them had positive IgM antibodies) compared with
2 out of 14 (14.3%) spontaneously cleared HCV patients
(where both patients had positive IgM antibodies). The
percentage of positive CMV DNA results is higher (P
value < 0.001) in chronic HCV patients compared to spon-
taneously cleared HCV patients, thus indicating a signifi-
cant association between HCV progression rate and CMV
reactivation. Moreover, the results confirmed that the
detection of CMV DNA by PCR in peripheral blood leu-
kocytes is a sensitive and reproducible procedure for
detecting viral infection. As the serological methods
reported to be insensitive and can’td i s t i n g u i s hb e t w e e n
CMV infection and CMV disease as IgM antibodies may
persist for months or years and may be detected during
reactivation of latent virus infections [19]. Recently,
DaPalma et al., [20] classified virus-virus interactions by
organizing them into three main categories: (1) direct
interactions of viral genes or gene products, (2) indirect
interactions that result from alterations in the host envir-
onment, and (3) immunological interactions, unique to
organisms equipped with an adaptive immune system. In
the present study the reason (s) why both HCMV IgM
(17.6% vs. 14.3%) and CMV DNA (29.4% vs. 14.3%) were
more frequently detected in healthy controls than in spon-
taneously cleared HCV subjects are not clear. However,
we may suggest that virus-induced changes that may affect
co-infecting viruses involve the innate immune mechan-
ism induced by type I interferon known as the antiviral
state. The antiviral state consists of increased expression
of a combination of enzymes, which if activated, shut
down cellular translation [21,22]. The most critical of
these enzymes are PKR and 2’-5’OAS. In negative control
group, CMV will replicate solely without the involvement
of another virus i.e. HCV which explains the higher preva-
l e n c eo fC M VD N Ai nc o n t r o l st h a ns p o n t a n e o u s l y
cleared HCV patients. In earlier studies on dual viral infec-
tions (HBV/CMV and HCV/CMV) [6,23] it was demon-
strated that CMV was detected in HBV or HCV patients
mostly as a dual infection and that it can aggravate the
course of the disease. Recently, Bader El din et al., [14]
reported higher rate of CMV co-infection in chronic HCV
Egyptian patients than those reported in other patient
populations. Whether HCV predisposes patients to CMV
infection or CMV predisposes patients to HCV is not
clear. Besides, Lian et al., [24] reported a high mortality
rate (85.7%) in CMV and HBV co-infected patients com-
pared to HBV infected patients only. Different studies
reported that CMV causes hepatitis with inflammation
and fibrosis of liver cells. That means CMV affects the
liver and overall immunological status of the host body
[6,14,25]. Bayram et al., [6] reported elevated liver enzymes
and marked histological changes in the liver of HCMV-
HCV co-infected patients. The serum levels of ALT and
AST enzymes showed a highly significant (P value <
0.001) elevation in positive HCMV DNA than in negative
subjects, thus suggesting a role of HCMV in liver patho-
genesis and support the results of Razonable et al., [26].
Furthermore, Rafael et al., [27] reported that HCMV infec-
tion interacted with HCV and raised the influence on the
liver enzymes and cause hepatitis. Considering the fact
that HCMV viruses exert an immunomodulatory effect
resulting in enhanced immunosuppression [28,29] and
cytokine dysregulation which could accelerate HCV patho-
genesis in critically ill patients, the findings of the present
study support the hypothesis that even low level of
HCMV replication doesn’t evolve into clinical disease it
significantly influences HCV outcome.
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